Outcomes of marginal zone lymphoma treated with ibrutinib in the first-line setting in the United States: a real-world analysis

Blood Adv. 2024 Feb 13;8(3):549-552. doi: 10.1182/bloodadvances.2023011698.
No abstract available

MeSH terms

  • Adenine
  • Humans
  • Lymphoma, B-Cell, Marginal Zone* / pathology
  • Piperidines
  • United States

Substances

  • ibrutinib
  • Adenine
  • Piperidines